Policy & Advocacy MassBio comments on termination of billions of dollars in indirect NIH funding Feb 10, 2025
Policy & Advocacy Statement on CMS listing 15 additional drugs subject to price negotiations Jan 17, 2025
Policy & Advocacy Post-Election Healthcare and Biotech Outlook: Implications for Massachusetts and Beyond Dec 05, 2024
Policy & Advocacy MassBio Op-Ed in STAT: How to keep the BIOSECURE Act from hobbling U.S. biotech and pharma Sep 12, 2024
Announcements Statement from MassBio CEO and President on the end of the legislative session Aug 01, 2024
